Skip to main content

Advertisement

Articles

Page 1 of 96

  1. Adjuvant radiotherapy (RT) for breast cancer (BC) has been associated with an increased risk of ischemic heart disease (IHD). We examined the incidence of IHD in a large population-based cohort of women with BC.

    Authors: Anna-Karin Wennstig, Charlotta Wadsten, Hans Garmo, Irma Fredriksson, Carl Blomqvist, Lars Holmberg, Greger Nilsson and Malin Sund

    Citation: Breast Cancer Research 2020 22:10

    Content type: Research article

    Published on:

  2. After the publication of this work [1] the authors have reported that in Table 3 The letter “T” in columns 5 and 7 should not be there.

    Authors: Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik…

    Citation: Breast Cancer Research 2020 22:9

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2019 21:133

  3. The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantiall...

    Authors: Nasim Mavaddat, Antonis C. Antoniou, Thea M. Mooij, Maartje J. Hooning, Bernadette A. Heemskerk-Gerritsen, Catherine Noguès, Marion Gauthier-Villars, Olivier Caron, Paul Gesta, Pascal Pujol, Alain Lortholary, Daniel Barrowdale, Debra Frost, D. Gareth Evans, Louise Izatt, Julian Adlard…

    Citation: Breast Cancer Research 2020 22:8

    Content type: Research article

    Published on:

  4. The p66ShcA redox protein is the longest isoform of the Shc1 gene and is variably expressed in breast cancers. In response to a variety of stress stimuli, p66ShcA becomes phosphorylated on serine 36, which allows...

    Authors: Kyle Lewis, Alex Kiepas, Jesse Hudson, Julien Senecal, Jacqueline R. Ha, Elena Voorand, Matthew G. Annis, Valerie Sabourin, Ryuhjin Ahn, Rachel La Selva, Sébastien Tabariès, Brian E. Hsu, Matthew J. Siegel, Matthew Dankner, Eduardo Cepeda Canedo, Mathieu Lajoie…

    Citation: Breast Cancer Research 2020 22:7

    Content type: Research article

    Published on:

  5. Distinguishing ductal carcinoma in situ (DCIS) from invasive ductal carcinoma (IDC) regions in clinical biopsies constitutes a diagnostic challenge. Spatial transcriptomics (ST) is an in situ capturing method,...

    Authors: Niyaz Yoosuf, José Fernández Navarro, Fredrik Salmén, Patrik L. Ståhl and Carsten O. Daub

    Citation: Breast Cancer Research 2020 22:6

    Content type: Research article

    Published on:

  6. Several dietary factors have been reported to be associated with risk of breast cancer, but to date, unequivocal evidence only exists for alcohol consumption. We sought to systematically assess the association...

    Authors: Alicia K. Heath, David C. Muller, Piet A. van den Brandt, Nikos Papadimitriou, Elena Critselis, Marc Gunter, Paolo Vineis, Elisabete Weiderpass, Guy Fagherazzi, Heiner Boeing, Pietro Ferrari, Anja Olsen, Anne Tjønneland, Patrick Arveux, Marie-Christine Boutron-Ruault, Francesca Romana Mancini…

    Citation: Breast Cancer Research 2020 22:5

    Content type: Research article

    Published on:

  7. Cancer stem cells (CSCs) are purported to be responsible for tumor initiation, treatment resistance, disease recurrence, and metastasis. CXCR1, one of the receptors for CXCL8, was identified on breast cancer (...

    Authors: Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato and Jenny C. Chang

    Citation: Breast Cancer Research 2020 22:4

    Content type: Research article

    Published on:

  8. Breast cancer metastasis is driven by a profound remodeling of the cytoskeleton that enables efficient cell migration and invasion. Anillin is a unique scaffolding protein regulating major cytoskeletal structu...

    Authors: Dongdong Wang, Nayden G. Naydenov, Mikhail G. Dozmorov, Jennifer E. Koblinski and Andrei I. Ivanov

    Citation: Breast Cancer Research 2020 22:3

    Content type: Research article

    Published on:

  9. Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy on gene express...

    Authors: Qiong Gao, Elena López-Knowles, Maggie Chon U. Cheang, James Morden, Ricardo Ribas, Kally Sidhu, David Evans, Vera Martins, Andrew Dodson, Anthony Skene, Chris Holcombe, Elizabeth Mallon, Abigail Evans, Judith M. Bliss, John Robertson, Ian Smith…

    Citation: Breast Cancer Research 2019 22:2

    Content type: Research article

    Published on:

  10. Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trast...

    Authors: Iain R. Macpherson, Pavlina Spiliopoulou, Saeed Rafii, Matilde Saggese, Richard D. Baird, Javier Garcia-Corbacho, Antoine Italiano, Jacques Bonneterre, Mario Campone, Nicola Cresti, John Posner, Yousuke Takeda, Akinori Arimura and James Spicer

    Citation: Breast Cancer Research 2019 22:1

    Content type: Research article

    Published on:

  11. Invasive lobular carcinomas (ILCs) account for 10–15% of all breast cancers. They are characterized by an elevated endocrine responsiveness and by a long lasting risk of relapse over time. Here we report for t...

    Authors: Fabio Conforti, Laura Pala, Eleonora Pagan, Giuseppe Viale, Vincenzo Bagnardi, Giulia Peruzzotti, Tommaso De Pas, Nadia Bianco, Rossella Graffeo, Elena Guerini Rocco, Andrea Vingiani, Richard D. Gelber, Alan S. Coates, Marco Colleoni and Aron Goldhirsch

    Citation: Breast Cancer Research 2019 21:153

    Content type: Research article

    Published on:

  12. PIK3CA mutations are frequent in human breast cancer. Pik3caH1047R mutant expression in mouse mammary gland promotes tumorigenesis. TP53 mutations co-occur with PIK3CA mutations in human breast cancers. We previo...

    Authors: Wenlin Yuan, Leonard D. Goldstein, Steffen Durinck, Ying-Jiun Chen, Thong T. Nguyen, Noelyn M. Kljavin, Ethan S. Sokol, Eric W. Stawiski, Benjamin Haley, James Ziai, Zora Modrusan and Somasekar Seshagiri

    Citation: Breast Cancer Research 2019 21:152

    Content type: Research article

    Published on:

  13. Breast cancer (BC) immune infiltrates play a critical role in tumor progression and response to treatment. Besides stromal tumor infiltrating lymphocytes (sTILs) which have recently reached level 1B evidence a...

    Authors: Iris Nederlof, Davide De Bortoli, Yacine Bareche, Bastien Nguyen, Michiel de Maaker, Gerrit K. J. Hooijer, Laurence Buisseret, Marleen Kok, Marcel Smid, Gert G. G. M. Van den Eynden, Arie B. Brinkman, Jan Hudecek, Jan Koster, Christos Sotiriou, Denis Larsimont, John W. M. Martens…

    Citation: Breast Cancer Research 2019 21:151

    Content type: Research article

    Published on:

  14. CDK4/6 inhibitors in combination with endocrine therapy (AE/AI/SERDs) are approved for the treatment of ER+ advanced breast cancer (BCa). However, not all patients benefit from CDK4/6 inhibitors therapy. We pr...

    Authors: Suryavathi Viswanadhapalli, Shihong Ma, Gangadhara Reddy Sareddy, Tae-Kyung Lee, Mengxing Li, Collin Gilbreath, Xihui Liu, Yiliao Luo, Uday P. Pratap, Mei Zhou, Eliot B. Blatt, Kara Kassees, Carlos Arteaga, Prasanna Alluri, Manjeet Rao, Susan T. Weintraub…

    Citation: Breast Cancer Research 2019 21:150

    Content type: Research article

    Published on:

  15. Breast cancer (BC) is the most common cancer in women, and despite the introduction of new screening programmes, therapies and monitoring technologies, there is still a need to develop more useful tests for mo...

    Authors: Daniel Fernandez-Garcia, Allison Hills, Karen Page, Robert K. Hastings, Bradley Toghill, Kate S. Goddard, Charlotte Ion, Olivia Ogle, Anna Rita Boydell, Kelly Gleason, Mark Rutherford, Adrian Lim, David S. Guttery, R. Charles Coombes and Jacqueline A. Shaw

    Citation: Breast Cancer Research 2019 21:149

    Content type: Research article

    Published on:

  16. A role for neural precursor cell-expressed developmentally downregulated gene 4 (NEDD4) in tumorigenesis has been suggested. However, information is lacking on its role in breast tumor biology. The purpose of ...

    Authors: Lingfeng Wan, Tao Liu, Zhipeng Hong, You Pan, Steven T. Sizemore, Junran Zhang and Zhefu Ma

    Citation: Breast Cancer Research 2019 21:148

    Content type: Research article

    Published on:

  17. Heterogeneity of immune gene expression patterns of luminal breast cancer (BC), which is clinically heterogeneous and overall considered as low immunogenic, has not been well studied especially in non-European...

    Authors: Bin Zhu, Lap Ah Tse, Difei Wang, Hela Koka, Tongwu Zhang, Mustapha Abubakar, Priscilla Lee, Feng Wang, Cherry Wu, Koon Ho Tsang, Wing-cheong Chan, Sze Hong Law, Mengjie Li, Wentao Li, Suyang Wu, Zhiguang Liu…

    Citation: Breast Cancer Research 2019 21:147

    Content type: Research article

    Published on:

  18. Addition of CDK4/6 inhibitors (CDK4/6i) to endocrine therapy significantly increased progression-free survival, leading to their approval and incorporation into the metastatic breast cancer treatment paradigm....

    Authors: Hitisha K. Patel, Nianjun Tao, Kyung-Min Lee, Mariela Huerta, Heike Arlt, Tara Mullarkey, Steven Troy, Carlos L. Arteaga and Teeru Bihani

    Citation: Breast Cancer Research 2019 21:146

    Content type: Research article

    Published on:

  19. The formation of neutrophil extracellular traps (NETs), known as NETosis, was first observed as a novel immune response to bacterial infection, but has since been found to occur abnormally in a variety of othe...

    Authors: Hunter T. Snoderly, Brian A. Boone and Margaret F. Bennewitz

    Citation: Breast Cancer Research 2019 21:145

    Content type: Review

    Published on:

  20. Breast cancer survivors are at risk for contralateral breast cancer (CBC), with the consequent burden of further treatment and potentially less favorable prognosis. We aimed to develop and validate a CBC risk ...

    Authors: Daniele Giardiello, Ewout W. Steyerberg, Michael Hauptmann, Muriel A. Adank, Delal Akdeniz, Carl Blomqvist, Stig E. Bojesen, Manjeet K. Bolla, Mariël Brinkhuis, Jenny Chang-Claude, Kamila Czene, Peter Devilee, Alison M. Dunning, Douglas F. Easton, Diana M. Eccles, Peter A. Fasching…

    Citation: Breast Cancer Research 2019 21:144

    Content type: Research article

    Published on:

  21. Metastatic triple-negative breast cancer (mTNBC), an aggressive histological subtype, has poor prognosis. Chemotherapy remains standard of care for mTNBC, although no agent has been specifically approved for t...

    Authors: Claire H. Li, Vassiliki Karantza, Gursel Aktan and Mallika Lala

    Citation: Breast Cancer Research 2019 21:143

    Content type: Research article

    Published on:

  22. Clinical application of cancer immunotherapy requires a better understanding of tumor immunogenicity and the tumor microenvironment. HLA class I molecules present antigens to CD8+ cytotoxic cells. Their loss or d...

    Authors: Bruno Valentin Sinn, Karsten E. Weber, Wolfgang Daniel Schmitt, Peter A. Fasching, William Fraser Symmans, Jens-Uwe Blohmer, Thomas Karn, Eliane Tabea Taube, Frederick Klauschen, Frederik Marmé, Christian Schem, Elmar Stickeler, Beyhan Ataseven, Jens Huober, Gunter von Minckwitz, Barbara Seliger…

    Citation: Breast Cancer Research 2019 21:142

    Content type: Research article

    Published on:

  23. Organoid cultures are increasingly used to model human cancers experimentally with a view to tailoring personalized medicine and predicting drug responses. Breast cancer is no exception, but in particular, pri...

    Authors: Nadine Goldhammer, Jiyoung Kim, Vera Timmermans-Wielenga and Ole William Petersen

    Citation: Breast Cancer Research 2019 21:141

    Content type: Short report

    Published on:

  24. Breast cancer is the most common cancer to affect women and one of the leading causes of cancer-related deaths. Proper regulation of cell cycle checkpoints plays a critical role in preventing the accumulation ...

    Authors: Bre-Anne Fifield, Ingrid Qemo, Evie Kirou, Robert D. Cardiff and Lisa Ann Porter

    Citation: Breast Cancer Research 2019 21:140

    Content type: Research article

    Published on:

  25. An increasing number of women are evaluated for potential breast cancer and may experience mental distress during evaluation. We aim to assess the risks of psychiatric disorders and cardiovascular diseases dur...

    Authors: Qing Shen, Anna Jöud, Maria E. C. Schelin, Arvid Sjölander, Yang Cao, Pär Sparén, Katja Fall, Kamila Czene, Unnur Valdimarsdóttir and Fang Fang

    Citation: Breast Cancer Research 2019 21:139

    Content type: Research article

    Published on:

  26. The tumor suppressor actions of hexamethylene bis-acetamide (HMBA)-inducible protein 1 (HEXIM1) in the breast, prostate, melanomas, and AML have been reported by our group and others. Increased HEXIM1 expressi...

    Authors: Monica M. Montano, I-Ju Yeh, Yinghua Chen, Chris Hernandez, Janna G. Kiselar, Maria de la Fuente, Adriane M. Lawes, Marvin T. Nieman, Philip D. Kiser, James Jacobberger, Agata A. Exner and Matthew C. Lawes

    Citation: Breast Cancer Research 2019 21:138

    Content type: Research article

    Published on:

  27. Liquid biopsies, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), can be used to understand disease prognosis, tumor heterogeneity, and dynamic response to treatment in metastatic br...

    Authors: Andrew A. Davis, Qiang Zhang, Lorenzo Gerratana, Ami N. Shah, Youbin Zhan, Wenan Qiang, Brian S. Finkelman, Lisa Flaum, Amir Behdad, William J. Gradishar, Leonidas C. Platanias and Massimo Cristofanilli

    Citation: Breast Cancer Research 2019 21:137

    Content type: Research article

    Published on:

  28. Available data proving the value of DWI for breast cancer diagnosis is mainly for enhancing masses; DWI may be less sensitive and specific in non-mass enhancement (NME) lesions. The objective of this study was...

    Authors: Daly Avendano, Maria Adele Marino, Doris Leithner, Sunitha Thakur, Blanca Bernard-Davila, Danny F. Martinez, Thomas H. Helbich, Elizabeth A. Morris, Maxine S. Jochelson, Pascal A. T. Baltzer, Paola Clauser, Panagiotis Kapetas and Katja Pinker

    Citation: Breast Cancer Research 2019 21:136

    Content type: Research article

    Published on:

  29. Endocrine therapies are still the main strategy for the treatment of oestrogen receptor-positive (ER+) breast cancers (BC), but resistance remains problematic. Cross-talk between ER and PI3K/AKT/mTORC has been...

    Authors: Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Sophie Chateau-Joubert, Lila Zabaglo, Margaret Hills, Andrew Dodson, Qiong Gao, Stephen R. Johnston, Mitch Dowsett, Sabina C. Cosulich, Elisabetta Maragoni and Lesley-Ann Martin

    Citation: Breast Cancer Research 2019 21:135

    Content type: Research article

    Published on:

  30. CGRRF1 is a growth suppressor and consists of a transmembrane domain and a RING-finger domain. It functions as a RING domain E3 ubiquitin ligase involved in endoplasmic reticulum-associated degradation. The ex...

    Authors: Yu-Ju Lee, Shiuh-Rong Ho, Joshua D. Graves, Yang Xiao, Shixia Huang and Weei-Chin Lin

    Citation: Breast Cancer Research 2019 21:134

    Content type: Research article

    Published on:

  31. The primary aim of NSABP FB-7 was to determine the pathologic complete response (pCR) rate in locally advanced HER2-positive (HER2+) breast cancer patients treated with neoadjuvant trastuzumab or neratinib or the...

    Authors: Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik…

    Citation: Breast Cancer Research 2019 21:133

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2020 22:9

  32. ERBB-2 is overexpressed in about 20% of breast cancers (BCs), indicating poor prognosis. The receptor activator of nuclear factor-κB (RANK) pathway is implicated in ERBB-2 (+) BC. The purpose of this study was...

    Authors: Ilianna Zoi, Michalis V. Karamouzis, Evangelia Xingi, Panagiotis Sarantis, Dimitra Thomaidou, Panayiotis Lembessis, Stamatios Theocharis and Athanasios G. Papavassiliou

    Citation: Breast Cancer Research 2019 21:132

    Content type: Research article

    Published on:

  33. Breast cancer is a leading cause of cancer-related death for women in the USA. Thus, there is an increasing need to investigate novel prognostic markers and therapeutic methods. Inflammation raises challenges ...

    Authors: Garhett L. Wyatt, Lyndsey S. Crump, Chloe M. Young, Veronica M. Wessells, Cole M. McQueen, Steven W. Wall, Tanya L. Gustafson, Yang-Yi Fan, Robert S. Chapkin, Weston W. Porter and Traci R. Lyons

    Citation: Breast Cancer Research 2019 21:131

    Content type: Research article

    Published on:

  34. Late-stage breast cancer preferentially metastasises to bone; despite advances in targeted therapies, this condition remains incurable. The lack of clinically relevant models for studying breast cancer metasta...

    Authors: Diane Lefley, Faith Howard, Fawaz Arshad, Steven Bradbury, Hannah Brown, Claudia Tulotta, Rachel Eyre, Denis Alférez, J. Mark Wilkinson, Ingunn Holen, Robert B. Clarke and Penelope Ottewell

    Citation: Breast Cancer Research 2019 21:130

    Content type: Research article

    Published on:

  35. Prophylactic mastectomy is the most effective intervention to prevent breast cancer. However, this major surgery has life-changing consequences at the physical, emotional, psychological, and social levels. The...

    Authors: Elizabeth Kenyon, Jennifer J. Westerhuis, Maximilian Volk, Jeremy Hix, Shatadru Chakravarty, Ethan Claucherty, Erin Zaluzec, Lisa Ramsey, Zach Madaj, Galen Hostetter, Bryn Eagleson, Erik Shapiro, Anna Moore and Lorenzo F. Sempere

    Citation: Breast Cancer Research 2019 21:129

    Content type: Research article

    Published on:

  36. Alcohol consumption and cigarette smoking are associated with an increased risk of breast cancer (BC), but it is unclear whether these associations vary by a woman’s familial BC risk.

    Authors: Nur Zeinomar, Julia A. Knight, Jeanine M. Genkinger, Kelly-Anne Phillips, Mary B. Daly, Roger L. Milne, Gillian S. Dite, Rebecca D. Kehm, Yuyan Liao, Melissa C. Southey, Wendy K. Chung, Graham G. Giles, Sue-Anne McLachlan, Michael L. Friedlander, Prue C. Weideman, Gord Glendon…

    Citation: Breast Cancer Research 2019 21:128

    Content type: Research article

    Published on:

  37. Nuclear receptor subfamily 1, group D, member 1 (NR1D1) is a ligand-regulated nuclear receptor and transcriptional factor. Although recent studies have implicated NR1D1 as a regulator of DNA repair and prolife...

    Authors: Hyelin Na, Jinil Han, Na-Lee Ka, Min-Ho Lee, Yoon-La Choi, Young Kee Shin and Mi-Ock Lee

    Citation: Breast Cancer Research 2019 21:127

    Content type: Research article

    Published on:

  38. Mutations in genes associated with homologous recombination (HR) increase an individual’s risk of developing triple-negative breast cancer (TNBC). Although known for their role in repairing dsDNA breaks, HR re...

    Authors: Scott J. Pearson, Jessica Elswood, Rola Barhoumi, Brittini Ming-Whitfield, Monique Rijnkels and Weston W. Porter

    Citation: Breast Cancer Research 2019 21:125

    Content type: Research article

    Published on:

  39. Women, who carry a germline BRCA1 gene mutation, have a markedly increased risk of developing breast cancer during their lifetime. While BRCA1 carriers frequently develop triple-negative, basal-like, aggressiv...

    Authors: Batzaya Davaadelger, Mi-Ran Choi, Hari Singhal, Susan E. Clare, Seema A. Khan and J. Julie Kim

    Citation: Breast Cancer Research 2019 21:124

    Content type: Research article

    Published on:

  40. Development of metastases and drug resistance are still a challenge for a successful systemic treatment in breast cancer (BC) patients. One of the mechanisms that confer metastatic properties to the cell relie...

    Authors: Simona Punzi, Chiara Balestrieri, Carolina D’Alesio, Daniela Bossi, Gaetano Ivan Dellino, Elena Gatti, Giancarlo Pruneri, Carmen Criscitiello, Giulia Lovati, Marine Meliksetyan, Alessandro Carugo, Giuseppe Curigliano, Gioacchino Natoli, Pier Giuseppe Pelicci and Luisa Lanfrancone

    Citation: Breast Cancer Research 2019 21:123

    Content type: Research article

    Published on:

  41. Earlier age at onset of pubertal events and longer intervals between them (tempo) have been associated with increased breast cancer risk. It is unknown whether the timing and tempo of puberty are associated wi...

    Authors: Lauren C. Houghton, Seungyoun Jung, Rebecca Troisi, Erin S. LeBlanc, Linda G. Snetselaar, Nola M. Hylton, Catherine Klifa, Linda Van Horn, Kenneth Paris, John A. Shepherd, Robert N. Hoover and Joanne F. Dorgan

    Citation: Breast Cancer Research 2019 21:122

    Content type: Research article

    Published on:

  42. In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC.

    Authors: William Jacot, Paul Cottu, Frederique Berger, Coraline Dubot, Laurence Venat-Bouvet, Alain Lortholary, Hugues Bourgeois, Marc Bollet, Veronique Servent, Elisabeth Luporsi, Marc Espié, Severine Guiu, Veronique D’Hondt, Veronique Dieras, Marie-Paule Sablin, Etienne Brain…

    Citation: Breast Cancer Research 2019 21:121

    Content type: Research article

    Published on:

  43. Lobular carcinoma in situ (LCIS) of the breast is a risk factor of developing invasive breast cancer. We evaluated the racial differences in the risks of subsequent invasive breast cancer following LCIS.

    Authors: Vanessa Dania, Ying Liu, Foluso Ademuyiwa, Jason D. Weber and Graham A. Colditz

    Citation: Breast Cancer Research 2019 21:120

    Content type: Research article

    Published on:

  44. Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC). Everolimus acts synergistically with eribulin in TNBC cell lines and xenograft models. ...

    Authors: Jin Sun Lee, Susan E. Yost, Suzette Blanchard, Daniel Schmolze, Hongwei Holly Yin, Raju Pillai, Kim Robinson, Aileen Tang, Norma Martinez, Jana Portnow, Wei Wen, John H. Yim, Heather Ann Brauer, Yuqi Ren, Thehang Luu, Joanne Mortimer…

    Citation: Breast Cancer Research 2019 21:119

    Content type: Research article

    Published on:

  45. Physical activity (PA) before and after breast cancer diagnosis has been reported to be associated with lower mortality. However, whether changes in the activity after diagnosis impact prognosis is unclear and...

    Authors: Audrey Y. Jung, Sabine Behrens, Martina Schmidt, Kathrin Thoene, Nadia Obi, Anika Hüsing, Axel Benner, Karen Steindorf and Jenny Chang-Claude

    Citation: Breast Cancer Research 2019 21:117

    Content type: Research article

    Published on:

  46. Given that breast cancer and normal dense fibroglandular tissue have similar radiographic attenuation, we examine whether automated volumetric density measures identify a differential change between breasts in...

    Authors: Kathleen R. Brandt, Christopher G. Scott, Diana L. Miglioretti, Matthew R. Jensen, Amir P. Mahmoudzadeh, Carrie Hruska, Lin Ma, Fang Fang Wu, Steven R. Cummings, Aaron D. Norman, Natalie J. Engmann, John A. Shepherd, Stacey J. Winham, Karla Kerlikowske and Celine M. Vachon

    Citation: Breast Cancer Research 2019 21:118

    Content type: Research article

    Published on:

  47. Triple-negative breast cancer has extremely high risk of relapse due to the lack of targeted therapies, intra- and inter-tumoral heterogeneity, and the inherent and acquired resistance to therapies. In this st...

    Authors: Agnieszka Morgenroth, Ebru Tinkir, Andreas T. J. Vogg, Ramya Ambur Sankaranarayanan, Fatima Baazaoui and Felix M. Mottaghy

    Citation: Breast Cancer Research 2019 21:116

    Content type: Research article

    Published on:

  48. Chemotherapy is a standard therapeutic regimen to treat triple-negative breast cancer (TNBC); however, chemotherapy alone does not result in significant improvement and often leads to drug resistance in patien...

    Authors: Jung Ok Lee, Min Ju Kang, Won Seok Byun, Shin Ae Kim, Il Hyeok Seo, Jeong Ah. Han, Ji Wook Moon, Ji Hae Kim, Su Jin Kim, Eun Jung Lee, Serk In Park, Sun Hwa Park and Hyeon Soo Kim

    Citation: Breast Cancer Research 2019 21:115

    Content type: Research article

    Published on:

  49. Screening mammography works better in fatty than in dense breast tissue. Computerized assessment of parenchymal texture is a non-subjective method to obtain a refined description of breast tissue, potentially ...

    Authors: My von Euler-Chelpin, Martin Lillholm, Ilse Vejborg, Mads Nielsen and Elsebeth Lynge

    Citation: Breast Cancer Research 2019 21:111

    Content type: Research article

    Published on:

Annual Journal Metrics

Advertisement